"The US Food and Drug Administration (FDA) has approved a foam containing calcipotriene and betamethasone dipropionate (Enstilar, Leo Pharma Inc) for topical treatment of plaque psoriasis in adults 18 years of age and older, according to a "...
Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with use of topical calcipotriene. [See WARNINGS AND PRECAUTIONS]
SORILUX (calcipotriene foam) Foam should not be used by patients with known hypercalcemia.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/2/2010
Additional Sorilux Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.